DE602005018043D1 - Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung - Google Patents
Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendungInfo
- Publication number
- DE602005018043D1 DE602005018043D1 DE602005018043T DE602005018043T DE602005018043D1 DE 602005018043 D1 DE602005018043 D1 DE 602005018043D1 DE 602005018043 T DE602005018043 T DE 602005018043T DE 602005018043 T DE602005018043 T DE 602005018043T DE 602005018043 D1 DE602005018043 D1 DE 602005018043D1
- Authority
- DE
- Germany
- Prior art keywords
- dihydrosphenomylinin
- liposomal formulations
- therapeutic agent
- compositions
- liposomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 239000002502 liposome Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57171204P | 2004-05-17 | 2004-05-17 | |
| US63199704P | 2004-11-30 | 2004-11-30 | |
| PCT/US2005/017054 WO2005120461A2 (en) | 2004-05-17 | 2005-05-16 | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602005018043D1 true DE602005018043D1 (de) | 2010-01-14 |
Family
ID=35169836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602005018043T Expired - Lifetime DE602005018043D1 (de) | 2004-05-17 | 2005-05-16 | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7811602B2 (de) |
| EP (1) | EP1750673B1 (de) |
| AT (1) | ATE450251T1 (de) |
| AU (1) | AU2005251691A1 (de) |
| CA (1) | CA2566559C (de) |
| DE (1) | DE602005018043D1 (de) |
| WO (1) | WO2005120461A2 (de) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6723338B1 (en) * | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
| AU2005291807B2 (en) | 2004-10-06 | 2012-04-19 | Bc Cancer Agency | Liposomes with improved drug retention for treatment of cancer |
| WO2006052767A2 (en) * | 2004-11-05 | 2006-05-18 | Inex Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal camptothecin formulations |
| US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
| CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
| JP5815915B2 (ja) * | 2005-10-11 | 2015-11-17 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | 過活動膀胱障害の治療のためのスフィンゴミエリンリポソーム |
| EP1959961A2 (de) * | 2005-12-06 | 2008-08-27 | Rigel Pharmaceuticals, Inc. | Formulierung aus unlöslichen kleinmoleküligen wirkstoffen in trägern auf fettbasis |
| WO2007127803A2 (en) | 2006-04-25 | 2007-11-08 | The Regents Of The University Of California | Administration of growth factors for the treatment of cns disorders |
| EP2023949A4 (de) * | 2006-04-26 | 2009-08-26 | Univ California | Zusammensetzungen und verfahren für konvektionsverstärkte freisetzung von neurotherapeutika mit hohem molekulargewicht |
| AU2007279674B2 (en) * | 2006-08-04 | 2013-10-03 | Megmilk Snow Brand Co., Ltd. | Agent for preventing infection |
| EP2197497B1 (de) * | 2007-09-27 | 2016-06-01 | ImmunoVaccine Technologies Inc. | Verwendung von liposomen in einem träger mit einer kontinuierlichen hydrophoben phase zur abgabe von polynucleotiden in vivo |
| US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| AU2009253780B2 (en) | 2008-06-05 | 2014-08-14 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| JP2012507565A (ja) | 2008-10-30 | 2012-03-29 | グオ・ペイシュエン | Ｄｎａのシークエンシング及び他の用途のための、膜に組み込まれたウイルスｄｎａパッケージングモータタンパク質コネクタバイオセンサ |
| JP2012520683A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| WO2010107957A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2010107955A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING |
| JP2012520686A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子６（ＳＴＡＴ６）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| JP2012521762A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いた神経成長因子β鎖（ＮＧＦβ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| JP2012521763A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子１（ＳＴＡＴ１）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| EA201171175A1 (ru) | 2009-03-27 | 2012-05-30 | Мерк Шарп Энд Домэ Корп. | Опосредованное phk-интерференцией ингибирование экспрессии гена межклеточной адгезионной молекулы 1 (icam-1) с использованием короткой интерферирующей нуклеиновой кислоты (sihk) |
| EP2411520A2 (de) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | Rna-interferenz-vermittelte hemmung der genexpression von tslp (thymic stromal lymphopoietin) unter verwendung von sina (short interfering nucleic acid) |
| US20120010272A1 (en) | 2009-03-27 | 2012-01-12 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| JP5622719B2 (ja) * | 2009-03-30 | 2014-11-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソーム組成物の製造方法 |
| PT2415470T (pt) | 2009-03-30 | 2016-08-31 | Eisai R&D Man Co Ltd | Composição de lipossomas |
| CA2781527C (en) * | 2009-09-23 | 2017-10-24 | Indu Javeri | Methods for the preparation of liposomes |
| US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
| US20110070294A1 (en) * | 2009-09-23 | 2011-03-24 | Javeri Indu | Methods for the Administration of Drugs Using Liposomes |
| EP2496700B1 (de) * | 2009-11-04 | 2017-03-01 | The University Of British Columbia | Nukleinsäurehaltige fettpartikel und entsprechende verfahren |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| EP2394640A1 (de) * | 2010-05-21 | 2011-12-14 | MediGene AG | Verbesserte liposomale Formulierungen von lipophilen Verbindungen |
| CN101912363A (zh) * | 2010-07-29 | 2010-12-15 | 蔡海德 | 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物 |
| WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| HUE044815T2 (hu) | 2010-08-17 | 2019-11-28 | Sirna Therapeutics Inc | Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával |
| JP6106085B2 (ja) | 2010-08-24 | 2017-03-29 | サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤 |
| WO2012027467A1 (en) | 2010-08-26 | 2012-03-01 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
| US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
| CA2850857C (en) | 2011-10-06 | 2022-07-26 | Immunovaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof |
| JP2015502337A (ja) | 2011-10-25 | 2015-01-22 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 限界サイズ脂質ナノ粒子および関連方法 |
| EP2788006A1 (de) | 2011-12-07 | 2014-10-15 | Alnylam Pharmaceuticals, Inc. | Bioabbaubare lipide zur wirkstofffreisetzung |
| ES2442450B1 (es) * | 2012-08-09 | 2014-12-12 | Enoc Solutions, S.L. | Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional |
| MX2015005992A (es) | 2012-11-20 | 2016-03-07 | Spectrum Pharmaceuticals Inc | Metodo mejorado para la preparacion de la vincristina liposomal encapsulada para el uso terapeutico. |
| US9636301B2 (en) | 2012-12-04 | 2017-05-02 | Arbutus Biopharma Corporation | In vitro release assay for liposome encapsulated vincristine |
| KR102255108B1 (ko) | 2013-03-08 | 2021-05-24 | 노파르티스 아게 | 활성제의 전달을 위한 지질 및 지질 조성물 |
| US9708354B2 (en) | 2013-03-15 | 2017-07-18 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| EP3842443B1 (de) | 2013-03-15 | 2025-02-19 | Cerenis Therapeutics Holding SA | Verfahren zur synthese von sphingomyelinen und dihydrosphingomyelinen |
| CA2906732C (en) | 2013-03-15 | 2023-08-08 | The University Of British Columbia | Lipid nanoparticles for transfection and related methods |
| EP4019506A1 (de) | 2013-12-19 | 2022-06-29 | Novartis AG | Lipide und lipidzusammensetzungen zur verabreichung von wirkstoffen |
| EP3083556B1 (de) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipide und lipidzusammensetzungen zur verabreichung von wirkstoffen |
| CN106795096B (zh) | 2014-06-25 | 2020-05-29 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
| WO2016010840A1 (en) | 2014-07-16 | 2016-01-21 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| ES2969956T3 (es) | 2014-09-05 | 2024-05-23 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| HRP20240865T1 (hr) | 2015-06-29 | 2024-10-11 | Acuitas Therapeutics Inc. | Lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina |
| TWI678213B (zh) | 2015-07-22 | 2019-12-01 | 美商史倍壯製藥公司 | 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物 |
| AU2016343803B2 (en) | 2015-10-28 | 2021-04-29 | Acuitas Therapeutics, Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2017078009A1 (ja) * | 2015-11-02 | 2017-05-11 | 富士フイルム株式会社 | リポソーム組成物およびその製造方法 |
| WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| EP3449921B1 (de) | 2016-04-28 | 2023-05-31 | Eisai R&D Management Co., Ltd. | Eribulin zur hemmung des tumorwachstums |
| DK3506909T3 (da) | 2016-09-02 | 2022-08-22 | Dicerna Pharmaceuticals Inc | 4'-phosphatanaloger og oligonukleotider omfattende samme |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| JP6728482B2 (ja) | 2017-03-31 | 2020-07-22 | 富士フイルム株式会社 | リポソーム組成物および医薬組成物 |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| EP4410317A3 (de) | 2017-04-28 | 2024-10-30 | Acuitas Therapeutics Inc. | Neue carbonyllipide und lipidnanopartikelformulierungen zur freisetzung von nukleinsäuren |
| WO2019036008A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
| WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
| EP3668834B1 (de) | 2017-08-17 | 2024-10-02 | Acuitas Therapeutics, Inc. | Lipide zur verwendung in lipidnanopartikelformulierungen |
| US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| EP3778611B1 (de) * | 2018-03-27 | 2022-10-12 | NOF Corporation | Lipid aus sphingomyelin und verfahren zu dessen herstellung |
| PL3811931T3 (pl) | 2018-06-20 | 2024-11-18 | Fujifilm Corporation | Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej |
| IL322436A (en) | 2018-09-21 | 2025-09-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| CN112789032A (zh) * | 2018-10-01 | 2021-05-11 | 富士胶片株式会社 | 包含内含药物的脂质体组合物及铂制剂的组合医药 |
| US11453639B2 (en) | 2019-01-11 | 2022-09-27 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| CN113924365A (zh) | 2019-03-29 | 2022-01-11 | 迪克纳制药公司 | 用于治疗kras相关疾病或病症的组合物和方法 |
| US11607386B2 (en) | 2019-04-03 | 2023-03-21 | New York University | Liposomes encapsulating adenosine |
| BR112021021686A2 (pt) | 2019-05-03 | 2022-03-22 | Dicerna Pharmaceuticals Inc | Moléculas inibidoras de ácido nucleico de fita dupla com fitas senso curtas |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| BR112022013821A2 (pt) | 2020-01-15 | 2022-09-13 | Dicerna Pharmaceuticals Inc | Ácidos nucleicos de 4?-o-metileno fosfonato e seus análogos |
| WO2022015809A2 (en) * | 2020-07-14 | 2022-01-20 | The Research Foundation for the State Universtiy of New York | Asymmetric charged vesicles and methods of preparing and use thereof |
| FI4182297T3 (fi) | 2020-07-16 | 2025-12-05 | Acuitas Therapeutics Inc | Kationisia lipidejä käytettäväksi lipidinanohiukkasissa |
| CA3187220A1 (en) | 2020-08-04 | 2022-02-10 | Dicerna Pharmaceuticals, Inc. | Systemic delivery of oligonucleotides |
| MX2023004371A (es) | 2020-10-14 | 2023-07-26 | George Mason Res Foundation Inc | Lípidos ionizables, y métodos de fabricación y uso de los mismos. |
| CN117440810A (zh) | 2021-05-24 | 2024-01-23 | 富士胶片株式会社 | 抗肿瘤剂 |
| EP4349338A4 (de) | 2021-05-24 | 2024-09-04 | FUJIFILM Corporation | Behandlungsmittel |
| AU2022368907A1 (en) | 2021-10-20 | 2024-05-02 | University Of Copenhagen | Rejuvenation treatment of age-related white matter loss |
| US12129223B2 (en) | 2021-12-16 | 2024-10-29 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| EP4658294A2 (de) | 2023-02-02 | 2025-12-10 | University of Rochester | Kompetitiver ersatz von gliazellen |
| WO2025090427A1 (en) | 2023-10-23 | 2025-05-01 | University Of Rochester | Glial-targeted relief of hyperexcitability in neurodegenerative diseases |
| WO2025166325A1 (en) | 2024-02-02 | 2025-08-07 | Editas Medicine, Inc. | MODIFIED GUIDE RNAs |
| WO2025213138A1 (en) | 2024-04-05 | 2025-10-09 | Editas Medicine, Inc. | Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5736155A (en) | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4857319A (en) | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
| US4885172A (en) | 1985-06-26 | 1989-12-05 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
| US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
| US5171578A (en) | 1985-06-26 | 1992-12-15 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4942184A (en) | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
| WO1990003795A1 (en) | 1988-10-05 | 1990-04-19 | Vestar, Inc. | Method of making liposomes with improved stability during drying |
| US4957773A (en) | 1989-02-13 | 1990-09-18 | Syracuse University | Deposition of boron-containing films from decaborane |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| JP2599492B2 (ja) | 1990-08-21 | 1997-04-09 | 第一製薬株式会社 | リポソーム製剤の製造法 |
| JPH09504517A (ja) | 1993-09-27 | 1997-05-06 | スミスクライン・ビーチャム・コーポレイション | カンプトテシン処方物 |
| WO1995012387A1 (en) | 1993-11-05 | 1995-05-11 | Amgen Inc. | Liposome preparation and material encapsulation method |
| US5534499A (en) | 1994-05-19 | 1996-07-09 | The University Of British Columbia | Lipophilic drug derivatives for use in liposomes |
| US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5858398A (en) * | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
| AU723163B2 (en) | 1995-06-07 | 2000-08-17 | Tekmira Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| CA2202103C (en) | 1996-04-11 | 2007-01-09 | Toshiaki Tagawa | Method for preparing closed vesicles |
| US5837282A (en) * | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| DE69943314D1 (de) * | 1998-02-12 | 2011-05-12 | Kapil N Bhalla | Sphingolipid-derivate und verfahren zu deren verwendung |
| US5981564A (en) | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
| US6723338B1 (en) | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
| US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| US6541508B2 (en) | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
| US6380405B1 (en) | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
| MXPA02012817A (es) * | 2000-06-30 | 2004-07-30 | Inex Pharmaceuticals Inc | Drogas antineoplasicas liposomales y uso de las mismas. |
| AU2001270310A1 (en) | 2000-07-07 | 2002-01-21 | Guilford Pharmaceuticals Inc. | Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same |
-
2005
- 2005-05-16 AU AU2005251691A patent/AU2005251691A1/en not_active Abandoned
- 2005-05-16 DE DE602005018043T patent/DE602005018043D1/de not_active Expired - Lifetime
- 2005-05-16 AT AT05783321T patent/ATE450251T1/de not_active IP Right Cessation
- 2005-05-16 US US11/131,436 patent/US7811602B2/en active Active
- 2005-05-16 EP EP05783321A patent/EP1750673B1/de not_active Ceased
- 2005-05-16 CA CA2566559A patent/CA2566559C/en not_active Expired - Fee Related
- 2005-05-16 WO PCT/US2005/017054 patent/WO2005120461A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20060008909A1 (en) | 2006-01-12 |
| US7811602B2 (en) | 2010-10-12 |
| ATE450251T1 (de) | 2009-12-15 |
| WO2005120461A3 (en) | 2006-03-16 |
| EP1750673A2 (de) | 2007-02-14 |
| CA2566559A1 (en) | 2005-12-22 |
| CA2566559C (en) | 2014-05-06 |
| AU2005251691A1 (en) | 2005-12-22 |
| EP1750673B1 (de) | 2009-12-02 |
| WO2005120461A2 (en) | 2005-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005018043D1 (de) | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung | |
| ES2534303T3 (es) | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN | |
| NO2017019I2 (no) | Enzalutamid eller et farmasøytisk akseptabelt salt derav | |
| SG164368A1 (en) | Treatment of cancer | |
| DE602004031462D1 (de) | Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung | |
| MXPA05013977A (es) | Metodos y composiciones para tratar enfermedades relacionadas con amiloide. | |
| SG160412A1 (en) | Anti-igfr1 antibody therapeutic combinations | |
| TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
| ATE537826T1 (de) | Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung | |
| DE60222573D1 (de) | Mikroemulsionbildende herbizidkonzentrate, mikroemulsionen und verfahren | |
| IL175158A0 (en) | Tocopherol-modified therapeutic drug compounds | |
| MX2007010996A (es) | Nuevas composiciones de liposomas. | |
| NO20063429L (no) | Brusende oral opiat doseringsform | |
| IL241756A0 (en) | Preparations and methods for the treatment of diseases of safty tumors | |
| CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
| DK1525177T3 (da) | Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf | |
| CR10147A (es) | "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos" | |
| WO2006020722A3 (en) | Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting | |
| CY1111263T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης | |
| UY27755A1 (es) | Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores. | |
| DE502004002571D1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
| DE60021381D1 (de) | Chinonverbindungen zur behandlung von krankheiten | |
| DE602004023183D1 (de) | Gegen antikörper gerichtete photodynamische therapie | |
| SI1781296T1 (sl) | Kinazolinski derivati in njihova uporaba pri zdravljenju trombocitemije | |
| GB0328180D0 (en) | Combination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |